Latest Breaking News On - Disease programs - Page 1 : comparemela.com

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Joern aldagMichael kaiserMark winderlichExchange commissionCompany onPharma incCompany typeEuropean medicines agencyDevelopment expensesGilead sciences incDrug administrationReports first quarterRecent businessPriority medicinesInvestigational new drugChief development officer

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data.

New yorkUnited statesCarolyn hawleyLaurence wattsR nolan townsendLexeo therapeutics incExchange commissionProgram updatesGlobenewswire incNolan townsendChief executive officerChromatography mass spectrometryAssay protein expressionFast trackOrphan drugDisease programs

HOOKIPA Pharma (HOOK) Provides Update on Business Priorities and Oncology Partnership Programs

HOOKIPA Pharma (HOOK) Provides Update on Business Priorities and Oncology Partnership Programs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Joern aldagHookipa pharma incChief executive officerDisease programs

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development.

Joern aldagMichael kaiserPharma incExchange commissionInvestigational new drugChief executive officerDisease programsHuman papillomavirusPrivate securities litigation reform actRoche collaboration agreement

HOOKIPA Pharma Provides Update on Business Priorities and

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious.

Michael kaiserJoern aldagPharma incExchange commissionInvestigational new drugChief executive officerDisease programsHuman papillomavirusPrivate securities litigation reform actRoche collaboration agreementNasdaq hookHookipa pharma incHookipa pharmaSb 200Head and neck cancer